PASITHEA THERAPEUTICS CORP. Operating Lease, Right-of-Use Asset, Amortization Expense
PASITHEA THERAPEUTICS CORP. (KTTA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $188.21 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-11-13
- PASITHEA THERAPEUTICS CORP. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $355.36K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2023-09-30 | $188.21K 10-Q · filed 2023-11-13 | ||
| 2023-03-31 | $355.36K 10-Q · filed 2023-05-12 | ||
| 2022-12-31 | $168.81K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |